… surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials …

A Du Bois, A Reuss, E Pujade‐Lauraine, P Harter… - Cancer, 2009 - Wiley Online Library
… A reverse separate analysis of the mucinous and serous subtypes showed that only complete
debulking and to some extent performance status had any significant prognostic impact in …

Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non–small …

H Yasuda, M Yamaya, K Nakayama… - Journal of clinical …, 2006 - ascopubs.org
… Factors associated with response rate such as age, sex, performance status, cancer cell
type, cancer staging, and use of nitroglycerin during chemotherapy were calculated with logistic …

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation …

JP van Meerbeeck, R Gaafar, C Manegold… - Journal of Clinical …, 2005 - ascopubs.org
… This study was a multicenter, randomized study comparing treatment with … randomization
was stratified for the following baseline stratification factors: institution, performance status (0 v …

Sequential vs concurrent chemoradiation for stage III non–small cell lung cancer: randomized phase III trial RTOG 9410

WJ Curran Jr, R Paulus, CJ Langer… - Journal of the …, 2011 - academic.oup.com
… At least five randomized trials ( 2–6 ) conducted since the early 1980s have demonstrated
a survival advantage for good performance status patients with stage III NSCLC when …

Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of …

K Swenerton, J Jeffrey, G Stuart, M Roy… - Journal of clinical …, 1992 - ascopubs.org
… torial analysis was performance status (P = .005): those with a performance status of 0 or 1
responded nearly twice as frequently (65%) as those with an impaired performance status (38…

Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial

T Ruers, F Van Coevorden, CJA Punt… - JNCI: Journal of the …, 2017 - academic.oup.com
… In this randomized phase II trial, we found that a combination of aggressive local treatment
plus systemic treatment, as compared with systemic treatment alone, improved both …

A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients …

IG Hwang, JH Ji, JH Kang, HR Lee, HY Lee… - Journal of geriatric …, 2017 - Elsevier
… -label, randomized phase III study. Other inclusion criteria were an Eastern Cooperative
Oncology Group (ECOG) performance status ≤ … The current randomized study was conducted in …

International atomic energy agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme

W Roa, L Kepka, N Kumar, V Sinaika… - Journal of Clinical …, 2015 - ascopubs.org
… However, the Stupp trial design only included patients younger than 70 years of age with an
Eastern Cooperative Oncology Group performance status of 0 to 2, and a subgroup analysis …

… and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 …

S Sundstrøm, RM Bremnes, S Kaasa… - Journal of Clinical …, 2002 - ascopubs.org
… an ECOG performance status 0 or 1. Thirteen patients incorrectly randomized as ECOG 3 …
The treatment arms were well balanced with regard to sex, age, and performance status, as …

A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy …

JD Cox, N Azarnia, RW Byhardt, KH Shin… - Journal of Clinical …, 1990 - ascopubs.org
… was made after stratifying patients by histopathologic type, presence or absence of nodal
metastasis, and performance status. The randomization scheme described by Zelen' …